Form 4: Biohaven CEO Coric Reports RSU Vesting & Tax Withholding

Biohaven Ltd. CEO Vlad Coric reported the vesting of 14,250 restricted share units and the withholding of 7,430 shares for tax purposes on January 5, 2026.

Summary

• Vlad Coric, Chief Executive Officer and Director of Biohaven Ltd., reported transactions involving common shares.
• On January 5, 2026, 14,250 common shares were acquired through the vesting of Restricted Share Units (RSUs) at a price of $0.
• Concurrently, 7,430 common shares were disposed of (withheld by the Issuer) to satisfy tax withholding requirements related to the RSU vesting, valued at $9.93 per share.
• Following these transactions, Coric directly beneficially owns 1,803,968 common shares.
• Coric also indirectly beneficially owns 1,195,275 common shares via The Vlad Coric Family Trust, 740,546 common shares via The Vladimir Coric Maric Trust, and 109,565 common shares via a 401(K) Plan.
• The original RSU grant was for 57,000 units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027, and 2028, contingent on continued service.

Sentiment

Score: 5

Explanation: The filing reports a routine, scheduled executive compensation event (RSU vesting and tax withholding) which is neutral in terms of company performance or strategic direction.

Positives

• The vesting of restricted share units indicates continued executive compensation and alignment of management interests with shareholders.
• The transaction is a routine compensation event, reflecting the company's ongoing executive incentive program.

Negatives

• The disposition of 7,430 shares for tax withholding reduces the direct beneficial ownership of the CEO, though this is a standard practice for RSU vesting.

Future Outlook

The remaining restricted share units from the January 5, 2025 grant are scheduled to vest in two equal installments on January 5, 2027, and January 5, 2028, subject to the reporting person's continued service with the Issuer.

Industry Context

This filing represents a routine insider transaction related to executive compensation, common across publicly traded companies. It reflects the scheduled vesting of equity awards as part of a long-term incentive plan, which is a standard practice in the biotechnology and pharmaceutical industry to align executive interests with shareholder value.

Comparison to Industry Standards

• The use of Restricted Share Units (RSUs) as a component of executive compensation is a widely adopted practice across industries, including biotechnology, aligning executive incentives with long-term company performance.
• The withholding of shares to cover tax obligations upon RSU vesting is a standard and efficient mechanism for managing tax liabilities associated with equity compensation, consistent with practices at comparable companies.

Related Party Transactions

• Common Shares are held indirectly by The Vlad Coric Family Trust and The Vladimir Coric Marital Trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and does not indicate any significant change in company strategy or financial health. It reflects the ongoing alignment of executive incentives.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Management: The vesting of RSUs represents a component of the CEO's compensation, reinforcing retention and performance incentives.

Next Steps

• Future installments of the restricted share unit award are scheduled to vest on January 5, 2027, and January 5, 2028.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled executive compensation event (RSU vesting and associated tax withholding). It does not provide new material information regarding the company's operational performance, financial outlook, or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on their existing fundamental analysis of Biohaven Ltd.

Keywords

Biohaven Ltd., BHVN, Vlad Coric, Restricted Share Units, RSU vesting, Insider transaction, SEC Form 4, Executive compensation, Share ownership